FindTrial
Sign In

ROLE OF SERUM ALPHA KLOTHO LEVEL IN BREAST CANCER

ROLE OF SERUM ALPHA KLOTHO ESTIMATION IN PATIENTS WITH CARCINOMA BREAST - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/10/058890
Enrollment
63
Registered
2023-10-19
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

Control Intervention1: nil: nil

Sponsors

Dr Karthika Remeshchandra M
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients with biopsy proven carcinoma breast who are previously untreated.

Exclusion criteria

Exclusion criteria: Patients who have undergone any treatment for ca breast Patients with h/o any other malignancy in the past/ present Patients with Chronic Kidney disease, Acute Kidney Injury, Heart failure

Design outcomes

Primary

MeasureTime frame
Serum alpha Klotho level & its association with various other parameters in patient with carcinoma breast & its role as possible biomarker in Neoadjuvent setting Timepoint: baseline, 6 months—

Secondary

MeasureTime frame
Association of serum Klotho level with pathological complete response in NACT settingTimepoint: baseline, 6 months—

Countries

India

Contacts

Public ContactDr Karthika Remeshchandra M

Kasturba Medical college, MAHE, Manipal

udupa.karthik@manipal.edu9845317153

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026